Emergent BioSolutions Inc.
EBS
Positions held
Your positionsEBS isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $349.17M | Enterprise value | $797.67M | Trailing P/E | — | Forward P/E | 6.51 |
| PEG | 0.38 | Price / book | 1.02 | Beta | 2.29 | Dividend yield | 0.00% |
| Revenue growth | 66.3% | Earnings growth | — | Gross margin | 50.4% | Operating margin | 28.3% |
| Profit margin | -23.0% | ROE | -40.3% | ROA | 6.9% | Debt / equity | 1.72 |
| Current ratio | 5.42 | Free cash flow | $40.00M | Analyst recommendation | none | Mean target | $11.00 |
| 52w high | $14.06 | 52w low | $4.36 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $227M | $150M | $144M | $222M | $130M | — |
| Op margin | 29.2% | 7.0% | -10.9% | 34.5% | 1.2% | — |
| Net income | -$180M | $6.8M | -$54.6M | $51.2M | -$12.0M | — |
| Gross margin | 57.2% | 51.9% | 41.0% | 61.3% | 48.7% | — |
| Gross profit | $130M | $77.7M | $58.9M | $136M | $63.4M | — |
| Operating income | $66.2M | $10.5M | -$15.7M | $76.5M | $1.6M | — |
- Revenue +52% vs prior quarter ($227M vs $150M).
- Gross margin 57.2% (was 51.9% prior quarter).
- Operating margin expanded to 29.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $705M | $1.0B | $1.0B | $1.1B |
| Op margin | 15.9% | -8.0% | -19.7% | -15.2% |
| Net income | $52.6M | -$191M | -$761M | -$212M |
| Gross margin | 53.7% | 32.8% | 31.0% | 35.6% |
| Gross profit | $379M | $332M | $318M | $383M |
| Operating income | $112M | -$81.5M | -$202M | -$163M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?
2026-10-06 · NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'
2026-09-15 · Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
2026-09-03 · Emergent BioSolutions Repurchases $75 Million of Senior Unsecured Notes Due 2028
2026-09-03 · Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
2026-09-01 · Emergent BioSolutions Wins $24 Million BARDA Contract for Anthrax Vaccine
2026-08-31 · Emergent BioSolutions Awarded Standing Offer for Narcan Nasal Spray in Canada
2026-08-31 · Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray
2026-08-12 · Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript
Price (daily)
Full chart · RSI · MACD · patterns